INTELLECTUAL PROPERTY (IP) FOR ADVANCING ASEAN’S VACCINE ECOSYSTEM | Episode 6: IP Commercialization and Valuation

This training is co-organized by the National Vaccine Institute (NVI) and the World Intellectual Property Organization (WIPO), in collaboration with the Regional Vaccine Manufacturing Collaborative (RVMC) and the ASEAN Secretariat (ASEC), under the ASEAN Vaccine Security and Self-Reliance (AVSSR) initiative.

The ASEAN region, home to over 600 million people, is continuing to strengthen its healthcare innovation and medical manufacturing capabilities through investments in research, development, and production. 

As public and private sector organizations work to advance vaccines, therapeutics, diagnostics, medical devices, and other health technologies, intellectual property (IP) is playing an increasingly important role in supporting innovation, attracting investment, enabling partnerships and facilitating technology transfer.

To help innovators and institutions better leverage their intellectual assets, the World Intellectual Property Organization (WIPO), in partnership with the National Vaccine Institute Thailand (NVI) and the Regionalized Vaccine Manufacturing Collaborative (RVMC), is organizing a training session on IP Commercialization and Valuation.